Alam Kamran 4
4 · Taysha Gene Therapies, Inc. · Filed Jan 27, 2026
Research Summary
AI-generated summary of this filing
Taysha Gene Therapies CFO Alam Kamran Sells Shares
What Happened
Alam Kamran, CFO of Taysha Gene Therapies (TSHA), reported two open-market sales to cover tax withholding on vested restricted stock units. On 2026-01-23 he disposed of 78,968 shares at a weighted average price of $4.75 for proceeds of $375,098. On 2026-01-26 he disposed of 23,849 shares at a weighted average price of $4.61 for proceeds of $109,944. Total proceeds across both transactions were about $485,042. These were sales (routine sell-to-cover for tax obligations), not purchases.
Key Details
- Transaction dates: 2026-01-23 (78,968 shares) and 2026-01-26 (23,849 shares).
- Reported weighted-average prices and ranges:
- 78,968 shares at $4.75 (prices ranged $4.635–$4.99 per footnote).
- 23,849 shares at $4.61 (prices ranged $4.505–$4.715 per footnote).
- Purpose: Mandatory sell-to-cover to satisfy income tax liabilities on RSU vesting (footnote F1).
- Filing: Form 4 filed 2026-01-27 (timely relative to the reported transaction dates).
- Shares owned after the transactions: not disclosed in the provided filing.
Context
- These transactions are tax-withholding sales tied to RSU vesting (routine administrative transactions) and do not necessarily indicate a change in insider sentiment.
- Footnotes note weighted-average pricing and offer to provide per-trade price details on request (useful if you want exact price-by-trade breakdown).
Insider Transaction Report
Form 4
Alam Kamran
CHIEF FINANCIAL OFFICER
Transactions
- Sale
Common Stock
[F1][F2]2026-01-23$4.75/sh−78,968$375,098→ 1,467,635 total - Sale
Common Stock
[F1][F3]2026-01-26$4.61/sh−23,849$109,944→ 1,443,786 total
Footnotes (3)
- [F1]The Reporting Person is selling the securities set forth herein pursuant to a mandatory sell-to-cover arrangement for the purpose of satisfying income tax liabilities incurred upon vesting of restricted stock unit awards only.
- [F2]The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.635 to $4.99 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2) and (3).
- [F3]The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.505 to $4.715 inclusive.
Signature
/s/ Kamran Alam|2026-01-27